Cargando…
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated th...
Autores principales: | Li, Jingxin, Hou, Lihua, Guo, Xiling, Jin, Pengfei, Wu, Shipo, Zhu, Jiahong, Pan, Hongxing, Wang, Xue, Song, Zhizhou, Wan, Jingxuan, Cui, Lunbiao, Li, Junqiang, Chen, Yin, Wang, Xuewen, Jin, Lairun, Liu, Jingxian, Shi, Fengjuan, Xu, Xiaoyu, Zhu, Tao, Chen, Wei, Zhu, Fengcai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863573/ https://www.ncbi.nlm.nih.gov/pubmed/35087233 http://dx.doi.org/10.1038/s41591-021-01677-z |
Ejemplares similares
-
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022) -
Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022) -
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022) -
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023) -
CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)